The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.

Bauer, J., N. Kohler, Y. Maringer, P. Bucher, T. Bilich, M. Zwick, S. Dicks, A. Nelde, M. Dubbelaar, J. Scheid, M. Wacker, J. S. Heitmann, S. Schroeder, J. Rieth, M. Denk, M. Richter, R. Klein, I. Bonzheim, J. Luibrand, U. Holzer, M. Ebinger, I. B. Brecht, M. Bitzer, M. Boerries, J. Feucht, H. R. Salih, H. G. Rammensee, S. Hailfinger, and J. S. Walz. 2022. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun 13: 6401. doi: 10.1038/s41467-022-33746-3.

Categorised in:

This post was written by Heike Ufheil